Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of “Buy” from Analysts

Gossamer Bio, Inc. (NASDAQ:GOSSGet Rating) has received a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.42.

A number of research analysts have commented on GOSS shares. HC Wainwright decreased their price objective on Gossamer Bio from $25.00 to $20.00 in a research report on Tuesday, April 26th. Piper Sandler decreased their price objective on Gossamer Bio from $26.00 to $15.00 in a research report on Monday, April 25th. Raymond James decreased their price objective on Gossamer Bio from $19.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 26th. UBS Group began coverage on Gossamer Bio in a research report on Wednesday, April 6th. They issued a “buy” rating and a $19.00 price target on the stock. Finally, Barclays reduced their price target on Gossamer Bio from $18.00 to $12.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 26th.

In related news, EVP Caryn Peterson sold 6,279 shares of the firm’s stock in a transaction on Wednesday, March 16th. The stock was sold at an average price of $8.28, for a total transaction of $51,990.12. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Laura Carter sold 5,002 shares of the firm’s stock in a transaction on Wednesday, March 16th. The stock was sold at an average price of $8.28, for a total value of $41,416.56. The disclosure for this sale can be found here. Insiders have sold a total of 42,300 shares of company stock worth $367,628 in the last ninety days. 8.00% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Teacher Retirement System of Texas acquired a new stake in shares of Gossamer Bio in the 1st quarter valued at about $89,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Gossamer Bio by 26.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,193 shares of the company’s stock valued at $115,000 after purchasing an additional 2,772 shares during the period. Dowling & Yahnke LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter valued at about $131,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio in the 3rd quarter valued at about $133,000. Finally, Belvedere Trading LLC acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at about $145,000. 76.90% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GOSS opened at $7.21 on Thursday. The firm has a market capitalization of $555.97 million, a price-to-earnings ratio of -2.31 and a beta of 1.12. The company has a debt-to-equity ratio of 1.47, a quick ratio of 8.32 and a current ratio of 8.32. The business’s fifty day moving average price is $8.59 and its two-hundred day moving average price is $10.02. Gossamer Bio has a 52 week low of $6.28 and a 52 week high of $14.30.

Gossamer Bio (NASDAQ:GOSSGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01. As a group, research analysts forecast that Gossamer Bio will post -2.71 EPS for the current year.

Gossamer Bio Company Profile (Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Featured Articles

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.